Display options
Share it on

Front Cardiovasc Med. 2021 Oct 14;8:763984. doi: 10.3389/fcvm.2021.763984. eCollection 2021.

Metabolic Profile in Neonatal Pig Hearts.

Frontiers in cardiovascular medicine

Pengsheng Li, Fan Li, Ling Tang, Wenjing Zhang, Yan Jin, Haiwei Gu, Wuqiang Zhu


  1. Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale, AZ, United States.
  2. Laboratory of Regenerative Medicine in Sports Science, School of Physical Education and Sports Science, South China Normal University, Guangzhou, China.
  3. College of Health Solutions, Arizona State University, Phoenix, AZ, United States.
  4. Department of Environmental Health Sciences, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, United States.
  5. Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Center for Translational Science, Florida International University, Port St. Lucie, FL, United States.

PMID: 34722687 PMCID: PMC8551694 DOI: 10.3389/fcvm.2021.763984


We evaluated the metabolic profile in pig hearts at postnatal day 1, 3, 7, and 28 (P1, P3, P7, and P28, respectively) using a targeted liquid chromatography tandem mass spectrometry assay. Our data showed that there is a clear separation of the detected metabolites in P1 vs. P28 hearts. Active anabolisms of nucleotide and proteins were observed in P1 hearts when cardiomyocytes retain high cell cycle activity. However, the active posttranslational protein modification, metabolic switch from glucose to fatty acids, and the reduced ratio of collagen to total protein were observed in P28 hearts when cardiomyocytes withdraw from cell cycle.

Copyright © 2021 Li, Li, Tang, Zhang, Jin, Gu and Zhu.

Keywords: heart; metabolism; metabolomics; neonatal; pig

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


  1. J Am Heart Assoc. 2018 Oct 16;7(20):e010378 - PubMed
  2. Circ Res. 2018 Jan 5;122(1):88-96 - PubMed
  3. Am J Physiol. 1997 Aug;273(2 Pt 1):E239-46 - PubMed
  4. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8372-E8381 - PubMed
  5. J Am Coll Cardiol. 1994 Apr;23(5):1204-8 - PubMed
  6. Circulation. 2018 Dec 11;138(24):2809-2816 - PubMed
  7. Circ Res. 2013 Aug 16;113(5):603-16 - PubMed
  8. Am J Cardiol. 1997 Aug 4;80(3A):17A-25A - PubMed
  9. Am J Physiol. 1991 Dec;261(6 Pt 2):H1698-705 - PubMed
  10. Science. 1965 Oct 15;150(3694):364-6 - PubMed
  11. Cell Rep. 2020 Sep 1;32(9):108087 - PubMed
  12. Methods Mol Biol. 2009;466:223-35 - PubMed
  13. J Am Heart Assoc. 2019 Jun 18;8(12):e012673 - PubMed
  14. Front Oncol. 2017 Dec 20;7:313 - PubMed
  15. Am J Physiol. 1994 Jan;266(1 Pt 2):H354-9 - PubMed
  16. EMBO Rep. 2020 Aug 5;21(8):e49752 - PubMed
  17. Science. 2011 Feb 25;331(6020):1078-80 - PubMed
  18. J Cardiovasc Pharmacol. 2010 Aug;56(2):130-40 - PubMed
  19. Mol Cell Biochem. 1998 Nov;188(1-2):49-56 - PubMed
  20. J Proteome Res. 2021 Sep 3;20(9):4303-4317 - PubMed
  21. J Appl Physiol. 1976 Jun;40(6):923-6 - PubMed
  22. Am J Physiol. 1977 Dec;233(6):H707-10 - PubMed
  23. Mol Ther Nucleic Acids. 2018 Dec 7;13:133-143 - PubMed
  24. Nucleic Acids Res. 2015 Feb 27;43(4):2466-85 - PubMed
  25. Cancer Res. 2018 Aug 15;78(16):4459-4470 - PubMed

Publication Types